Robert W. Baird Issues Positive Forecast for Certara (NASDAQ:CERT) Stock Price

Certara (NASDAQ:CERT) had its price objective increased by Robert W. Baird from $9.00 to $13.00 in a research note published on Friday morning,Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

A number of other brokerages have also weighed in on CERT. Barclays reduced their price objective on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating on the stock in a report on Thursday. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price target for the company. Finally, Stephens reiterated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Certara currently has a consensus rating of “Moderate Buy” and an average target price of $15.50.

Certara Stock Up 22.8 %

Shares of NASDAQ:CERT opened at $12.91 on Friday. Certara has a fifty-two week low of $8.64 and a fifty-two week high of $17.94. The firm’s 50 day moving average price is $11.61 and its 200 day moving average price is $11.37. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -64.55, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64.

Institutional Trading of Certara

Institutional investors and hedge funds have recently made changes to their positions in the company. Versant Capital Management Inc grew its stake in Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock worth $27,000 after buying an additional 1,866 shares during the last quarter. Venturi Wealth Management LLC grew its position in shares of Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after acquiring an additional 2,509 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after acquiring an additional 1,047 shares during the period. Johnson Financial Group Inc. acquired a new position in shares of Certara in the 4th quarter valued at $47,000. Finally, Blue Trust Inc. raised its position in Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after purchasing an additional 822 shares during the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.